Back

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes mellitus: a systematic review and meta-analysis with over 10,000 patients

29 August 2017 (16:48 - 17:06)
Organised by:
Congress Presentation Part of: Cholesterol-lowering therapy for primary and secondary prevention Lipids (Epidemiology and Prevention) ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Luiz Sergio Carvalho

Sirio Libanes Hospital, Brasilia (Brazil)

4 More presentations in this session

Presentation thumbnail
State of the Art: cholesterol-lowering therapy for primary and secondary prevention
Doctor J. Robinson (Iowa, US)
Slides Video
Presentation thumbnail
Effect of the magnitude of LDL lowering on the incidence of cataract among patients treated with statins or PCSK9 antibodies
Doctor J. Kostis (New Brunswick, US)
Abstract Slides Video
Presentation thumbnail
Comparison of the low-density lipoprotein cholesterol target value and the preventive effect of statins in elderly patients and younger patients
Doctor A. Endo (Izumo, JP)
Abstract Slides Video
Presentation thumbnail
Lipid-lowering therapy in primary prevention: where will we be 10 years from now
Professor A. Catapano (Milan, IT)

Access the full session

Session thumbnail
Cholesterol-lowering therapy for primary and secondary prevention

The Event

Event poster

ESC Congress 2017

29 August 2017 16:48 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources